Your browser is no longer supported. Please, upgrade your browser.
ENOB Enochian Biosciences Inc. daily Stock Chart
Enochian Biosciences Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own0.10% Shs Outstand46.04M Perf Week-3.38%
Market Cap262.89M Forward P/E- EPS next Y- Insider Trans- Shs Float14.00M Perf Month30.07%
Income-18.00M PEG- EPS next Q- Inst Own2.60% Short Float5.31% Perf Quarter30.37%
Sales- P/S- EPS this Y-66.80% Inst Trans0.67% Short Ratio15.04 Perf Half Y-5.62%
Book/sh4.44 P/B1.29 EPS next Y- ROA-10.30% Target Price- Perf Year-9.37%
Cash/sh0.27 P/C21.37 EPS next 5Y- ROE-11.60% 52W Range2.91 - 9.50 Perf YTD-18.43%
Dividend- P/FCF- EPS past 5Y-8.70% ROI- 52W High-40.00% Beta0.14
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low95.88% ATR0.55
Employees8 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)59.11 Volatility6.64% 12.97%
OptionableNo Debt/Eq0.00 EPS Q/Q413.40% Profit Margin- Rel Volume0.16 Prev Close5.71
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume49.47K Price5.70
Recom- SMA2010.07% SMA5013.69% SMA200-1.34% Volume1,318 Change-0.18%
Oct-31-19 04:17PM  Penny Stocks to Buy Using Technical Analysis for November 2019 Investopedia
Oct-26-19 10:18AM  We're Not Very Worried About Enochian Biosciences's (NASDAQ:ENOB) Cash Burn Rate Simply Wall St.
Jun-03-19 07:00AM  Enochian BioSciences Inventor Named to Two Important Scientific Committees GlobeNewswire
Apr-29-19 09:19AM  Enochian Biosciences (NASDAQ:ENOB) Shareholders Have Enjoyed A 37% Share Price Gain Simply Wall St. -8.15%
Mar-07-19 12:45PM  Successful Treatment of London Patient Underscores Clinical Potential of Enochian Biosciences Gene Modified Cellular Therapy for HIV GlobeNewswire -6.88%
Feb-01-19 02:31PM  4 Healthcare Stocks Looking To Start February Off Strong ACCESSWIRE +9.88%
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +10.00%
Jan-07-19 08:30AM  Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair GlobeNewswire
Jan-04-19 08:00AM  How Much Of Enochian Biosciences Inc. (NASDAQ:ENOB) Do Insiders Own? Simply Wall St.
Dec-05-18 08:30AM  Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol ENOB GlobeNewswire
Dec-03-18 08:30AM  Enochian Biosciences to Present at Biotech Showcase 2019 GlobeNewswire
Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.